EdiGene
PrivateLast Round
Series B
Extension
Apr 21, 2021
Total Funding Raised
$160M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
EdiGene is a biotechnology company that develops genome editing technologies to accelerate drug discovery and create novel therapeutics for genetic diseases and cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EdiGene Comparables
Compare EdiGene with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BRL Medicine Inc. | 87% | |
| Shanghai Bendao Gene Technology | 84% | |
| AIRNA | 80% |
EdiGene Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 21, 2021 | ||||
| Series B | Oct 13, 2020 | ||||
| Series A Extension | Sep 16, 2019 | ||||
| Series A Extension | Feb 4, 2019 | ||||
| VC Round | Aug 24, 2018 |
EdiGene Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alwin Capital | Series B Extension, Series B |
| BioTrack Capital | Series B Extension |
| BGI Co-Win | VC Round |
| Loyal Valley Capital | Series B Extension |
| IDG Capital | VC Round, Series B Extension, Series B, Series A Extension, Series A |
| Sincere Capital | VC Round, Series B |
| WI Harper Group | Series A, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 7, 2026
Open roles increased to 40, 87% of headcount.
- Aug 31, 2026
Open roles increased to 34, 74% of headcount.
EdiGene Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EdiGene's valuation, stock price, and market status.
Is EdiGene a public or private company?
EdiGene is a private company.
What is the current stock price of EdiGene?
EdiGene is a private company with no public stock price. No recent secondary market data is available.
How much is EdiGene worth (valuation)?
Valuation information for EdiGene is not publicly available.
Can I buy EdiGene stock?
EdiGene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was EdiGene's last funding round?
EdiGene's most recent funding round was Series B Extension on April 21, 2021.
Who are the main investors in EdiGene?
Key investors in EdiGene include Loyal Valley Capital, IDG Capital, 3H Health Investment, Lilly Asia Ventures, 松禾资本 (Green Pine Capital Partners).
Will EdiGene IPO soon?
No public IPO plans have been announced for EdiGene.
How can I track EdiGene secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EdiGene's secondary market activity and sign up for updates.